Spravato (esketamine) is a supervised, in-clinic nasal-spray treatment that may be considered for eligible adults after psychiatric and medical review.
What a treatment visit involves
The source practices describe an initial evaluation followed, when appropriate, by scheduled clinic sessions. The patient uses the nasal spray in the office and remains under observation for approximately two hours while staff monitor comfort, blood pressure, response, and possible side effects.
Eligibility and frequency are individualized and subject to current prescribing, monitoring, and coverage requirements. Staff will explain transportation and post-treatment instructions before the first session.
What care may include
- Review of depression history and previous treatments
- Eligibility, medication, and safety assessment
- Explanation of risks, benefits, alternatives, and treatment schedule
- Self-administration in the clinic under staff supervision
- Vital-sign and side-effect monitoring during the required observation period
- Ongoing evaluation and coordination with other treatment
Care begins with an individualized assessment. Availability, clinical fit, age ranges, location, telehealth eligibility, and treatment recommendations vary by provider. Contact the office to confirm current options.